Difference between revisions of "Decitabine (Dacogen)"
(updated content) |
m |
||
Line 8: | Line 8: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
− | == | + | ==History of changes in FDA indication== |
− | * | + | * 5/2/2006: Initial approval for treatment of patients with [[Myelodysplastic syndrome | myelodysplastic syndromes (MDS)]] including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. |
− | |||
==Patient drug information== | ==Patient drug information== | ||
Line 23: | Line 22: | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Nucleic acid analogs]] | [[Category:Nucleic acid analogs]] | ||
+ | |||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Myelodysplastic syndrome medications]] | [[Category:Myelodysplastic syndrome medications]] | ||
+ | |||
+ | [[Category:Drugs FDA approved in 2006]] |
Revision as of 19:05, 28 June 2014
Also known as 5-aza-2'-deoxycytidine.
General information
Class/mechanism: Pyrimidine/cytosine analog, DNA hypomethylating agent. Incorporates into DNA and inhibits DNA methyltransferase, causing DNA hypomethylation, which results in cellular differentiation or apoptosis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
History of changes in FDA indication
- 5/2/2006: Initial approval for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Patient drug information
- Decitabine (Dacogen) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on pages 8-9 of the Decitabine (Dacogen) package insert[1]
- Decitabine (Dacogen) patient drug information (UpToDate)[5]